Article
Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms.
Cancer discovery - 1 May 2024
Dunbar Andrew J, Bowman Robert L, Park Young C, O'Connor Kavi, Izzo Franco, Myers Robert M, Karzai Abdul, Zaroogian Zachary, Kim Won Jun, Fernández-Maestre Inés, Waarts Michael R, Nazir Abbas, Xiao Wenbin, Codilupi Tamara, Brodsky Max, Farina Mirko, Cai Louise, Cai Sheng F, Wang Benjamin, An Wenbin, Yang Julie L, Mowla Shoron, Eisman Shira E, Hanasoge Somasundara Amritha Varshini, Glass Jacob L, Mishra Tanmay, Houston Remie, Guzzardi Emily, Martinez Benitez Anthony R, Viny Aaron D, Koche Richard P, Meyer Sara C, Landau Dan A, Levine Ross L
Abstract excerpt
Gain-of-function mutations activating JAK/STAT signaling are seen in the majority of patients with myeloproliferative neoplasms (MPN), most commonly JAK2V617F. Although clinically approved JAK inhibitors improve symptoms and outcomes in MPNs, remissions are rare, and mutant allele burden does not substantively change with chronic therapy. We hypothesized this is due to limitations of current JAK inhibitors to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.